Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD
J Clin Oncol. 2013 31 (4): 482-9

PMID: 23248257 · PMCID: PMC4878037 · DOI:10.1200/JCO.2012.43.5966

MeSH Terms (19)

Adult Aged Antineoplastic Agents Disease-Free Survival Female Humans Kaplan-Meier Estimate Male MAP Kinase Kinase 1 MAP Kinase Kinase 2 Melanoma Middle Aged Mutation Neoplasm Staging Proto-Oncogene Proteins B-raf Pyridones Pyrimidinones Skin Neoplasms Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: